Stempoint Capital LP Has $2.05 Million Position in Twist Bioscience Corporation $TWST

Stempoint Capital LP lessened its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 91.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 43,110 shares of the company’s stock after selling 475,245 shares during the period. Stempoint Capital LP’s holdings in Twist Bioscience were worth $2,049,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Royal Bank of Canada increased its holdings in shares of Twist Bioscience by 11.8% in the first quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after purchasing an additional 4,254 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Twist Bioscience by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after purchasing an additional 3,181 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock worth $36,629,000 after buying an additional 37,577 shares during the last quarter. Intech Investment Management LLC lifted its stake in shares of Twist Bioscience by 18.9% during the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after buying an additional 4,591 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Twist Bioscience during the 2nd quarter worth about $737,000.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TWST. Piper Sandler began coverage on shares of Twist Bioscience in a research note on Thursday, June 11th. They issued an “overweight” rating and a $85.00 price target on the stock. TD Cowen raised their price objective on shares of Twist Bioscience from $68.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Leerink Partners set a $110.00 price objective on Twist Bioscience in a report on Thursday, July 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Finally, Barclays increased their target price on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.30.

Twist Bioscience Trading Down 3.5%

Shares of Twist Bioscience stock opened at $85.47 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70. The firm has a 50-day moving average of $83.72 and a 200-day moving average of $61.36. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $105.47. The stock has a market cap of $5.32 billion, a PE ratio of -64.26 and a beta of 2.11.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business had revenue of $110.72 million for the quarter, compared to the consensus estimate of $107.64 million. During the same period in the prior year, the business posted ($0.66) earnings per share. Twist Bioscience’s revenue was up 19.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Twist Bioscience Corporation will post -2.02 EPS for the current year.

Insider Activity

In other news, SVP Paula Green sold 291 shares of Twist Bioscience stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the completion of the sale, the senior vice president directly owned 120,414 shares in the company, valued at approximately $10,514,550.48. The trade was a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jan Johannessen sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total value of $673,440.00. Following the completion of the sale, the director owned 17,754 shares of the company’s stock, valued at approximately $996,354.48. This trade represents a 40.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 50,211 shares of company stock worth $4,199,331. Insiders own 3.08% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.